GPCR vs. SDGR, HRMY, EWTX, KURA, SUPN, PTGX, TARO, SYRE, RCUS, and LGND
Should you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include Schrödinger (SDGR), Harmony Biosciences (HRMY), Edgewise Therapeutics (EWTX), Kura Oncology (KURA), Supernus Pharmaceuticals (SUPN), Protagonist Therapeutics (PTGX), Taro Pharmaceutical Industries (TARO), Spyre Therapeutics (SYRE), Arcus Biosciences (RCUS), and Ligand Pharmaceuticals (LGND). These companies are all part of the "pharmaceutical preparations" industry.
Schrödinger (NASDAQ:SDGR) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Schrödinger received 33 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 78.95% of users gave Structure Therapeutics an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.
79.1% of Schrödinger shares are held by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are held by institutional investors. 7.6% of Schrödinger shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Structure Therapeutics has a net margin of 0.00% compared to Structure Therapeutics' net margin of -75.94%. Structure Therapeutics' return on equity of -29.25% beat Schrödinger's return on equity.
Schrödinger presently has a consensus target price of $42.80, indicating a potential upside of 88.05%. Structure Therapeutics has a consensus target price of $85.71, indicating a potential upside of 137.11%. Given Schrödinger's stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Schrödinger.
In the previous week, Schrödinger and Schrödinger both had 4 articles in the media. Schrödinger's average media sentiment score of 0.68 beat Structure Therapeutics' score of 0.44 indicating that Structure Therapeutics is being referred to more favorably in the news media.
Schrödinger has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks.
Summary
Schrödinger and Structure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Structure Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Structure Therapeutics Competitors List
Related Companies and Tools
